Collegium Pharmaceutical (NASDAQ:COLL) will be issuing its quarterly earnings data after the market closes on Thursday, November 8th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.02. Collegium Pharmaceutical had a negative net margin of 39.10% and a negative return on equity of 61.82%. The firm had revenue of $73.10 million for the quarter, compared to analyst estimates of $72.21 million. The company’s revenue was up 1930.6% compared to the same quarter last year. On average, analysts expect Collegium Pharmaceutical to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NASDAQ COLL opened at $16.05 on Thursday. Collegium Pharmaceutical has a one year low of $9.01 and a one year high of $29.90. The company has a debt-to-equity ratio of 3.94, a quick ratio of 0.78 and a current ratio of 0.82. The company has a market capitalization of $542.18 million, a P/E ratio of -6.50 and a beta of 0.42.
In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $16.53, for a total value of $413,250.00. Following the completion of the sale, the director now owns 361,000 shares of the company’s stock, valued at $5,967,330. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 13.87% of the company’s stock.
COLL has been the topic of several research reports. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, August 8th. BidaskClub lowered shares of Collegium Pharmaceutical from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 18th. HC Wainwright restated a “buy” rating on shares of Collegium Pharmaceutical in a report on Monday, September 17th. Piper Jaffray Companies set a $34.00 price target on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a report on Wednesday, July 11th. Finally, Cantor Fitzgerald set a $35.00 price target on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a report on Wednesday, October 24th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $31.71.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Read More: NASDAQ Stock Market Explained
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.